AGCT closes financing round
Marburg, January 3, 2019, AGCT closes financing round to accelerate revolutionary assay technology development for oncology market
AGCT announces the closing of a substantial financing round with existing investors and two investment companies. The financing followed a technology milestone achievement demonstrating the performance of AGCT’s proprietary cyberPCR technology. cyberPCR is a novel PCR-based method that AGCT believes has the power to significantly improve the early detection of circulating tumor DNA from cancer liquid biopsies over existing assay technologies. The unique advantage of cyberPCR is the exclusive amplification of tumor-derived DNA over non-tumor DNA, the latter being much more abundant in a patient’s blood sample making the detection of rare tumor molecules inherently difficult. AGCT’s cyberPCR technology does not require any dedicated instrumentation and can be used with existing PCR equipment. The funds will be used to grow AGCT’s internal R&D and further development of the assay technology for the oncology market.